ABSTRACT
Levocetirizine hydrochloride is an orally active, non-sedative antihistamine used in the
symptomatic relief of seasonal and perennial allergic rhinitis. The main objective of the proposed study
is to develop and validate a dissolution method of Levocetirizine hydrochloride dosage form by reverse
phase HPLC isocratic method. The method is optimized by various filteration methods such as centrifuge
and whatman 42. The filteration methods are evaluated by reverse phase isocratic HPLC method using
column – Phenomenex Luna – C 18 (250 mm x 4.6 mm; 5 µ), mobile phase – mixture of buffer and
acetonitrile (580:420), adjusted pH to 6.0 with 10 % sodium hydroxide. buffer – 4.08 g Potassium
dihydrogen orthophosphate in 600 mL of water. The flow rate is 1.0 mL/min and the elutant is monitored
at 230 nm with UV detector. The retention time of levocetirizine hydrochloride is 5.5. Precision shows
that % relative standard deviation is about 1.1%. The percentage recovery of the levocetirizine from the
dosage formulation is 99.6%. The results obtained for robustness and ruggedness of levocetirizine
hydrochloride are well within the acceptance criteria. The proposed method is found to be simple, rapid,
accurate and precise. The proposed methods are validated as per ICH guidelines and successfully applied
for the determination of Levocetirizine tablet.
References
[1] Suresh B, Osborne J. L. Quick dissolving films- A novel approach to drug delivery.
Available from: http://www.drugdeliverytechnology.com. [Last accessed on 2011 Jan
10].
[2] Rekha MR, Chandra PS. Trends Biomater Artif Organs. 20 (2007) 1-6.
[3] Diab T, Biliaderis CG, Gerasopoulos D, Sfakiotakis E. J Sci Food Agric. 81 (2001) 988-
1000.
[4] Revathi V. Fast Dissolving drug delivery system. Pharma Times 39 (2007) 22-3.
[5] Felton L. A, O’Donnell P.B., McGinity J. W. Aqueous polymeric coatings for
pharmaceutical dosage forms. New York, USA: Informa health; 2008. Mechanical
properties of polymeric films prepared from aqueous dispersions; pp. 176-178.
[6] Web ref. Available from: http://en.wikipedia.org/wiki/Levocetirizine. [Lastaccessed on
2008 Sept 23].
[7] Tillement JP, Testa B, Brée F., Biochem. Pharmacol. 66 (2003) 1123-1126.
[8] Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Brazilian J. Clin.
Pharmacol. 60 (2005) 24-31.
[9] Potter PC; Study Group. Allergy. 58 (2003) 893-899.
[10] Kapp A, Pichler W.J., Int J. Dermatol. 45 (2006) 469-474.
[11] Mashru RC, Sutariya VB, Sankalia MG, Parikh PP., Drug Dev. Ind. Pharm. 35 (2005)
25-34.
[12] Brindle LP, Krochta JM., J. Food Sci. 73 (2008) 446-454.
[13] Doaa A. E, Nevine S. A., AAPS Pharm. Sci. Tech. 11 (2010) 1018-1024
[14] Uddhav B, Kishore G, Nancy P, Sanjeevani A, Shalaka D., Int. J. Pharm. Sci. 2 (2010)
76-80.
[15] Mahesh A, Shastri N, Sadanadam M., Current Drug Deliv. 7 (2010) 21-27.
[16] Mishra R, Amin A. Indian J. Pharm. Educ. Res. 45 (2011) 71-77.
[17] Dinge A, Nagarsenker M., AAPS Pharm. Sci. Tech. 9 (2008) 349-356.
[18] The Formulary US, Rockyvilley USP. The United State pharmacopoeial Convention
Inde. NF 32 2014; USP 37.
[19] ICH (International Conference on Harmonization) – Guidelines Q2A, Validation of
Analytical Procedures: Definition and terminology (CPMP III/5626/94) March Geneva,
Switzerland. Journal of AOAC International 1995.
[20] ICH (International Conference on Harmonization) – Guidelines Q2B, Validation of
Analytical Procedures: Methodology (CPMP/ICH/281/95) November Geneva,
Switzerland. Journal of AOAC International 1996.
[21] British pharmacopoeia: The Stationery Office, London, 1 (2007) 1036-1037.
[22] Prabhakara Prabhu et. al., Int. J. Pharm. Invest. 1 (2011) 240-246.
[23] Rathore A. S., Sathiyanarayanan L, Mahadik K. R., Pharm. Anal. Acta. 1 (2010) 106.
Download all article in PDF
Support the magazine and subscribe to the content
This is premium stuff. Subscribe to read the entire article.
